Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
Xiangdong Lv, Xuan Lu, Jin Cao, et al.
Science (2023) Vol. 381, Iss. 6662
Open Access | Times Cited: 50

Showing 26-50 of 50 citing articles:

F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression
Feng Li, Hongqiang Yu, Yujun Zhang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Unconventional strategy could be the future: From target to KRAS broad range treatment
Sara Fancelli, Giulia Petroni, Serena Pillozzi, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e29739-e29739
Open Access | Times Cited: 3
Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors
K. Wang, Xin Zhang, Yufei Fan, et al.
Redox Biology (2024) Vol. 78, pp. 103419-103419
Open Access | Times Cited: 3
Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex
Andreas Damianou, Zhu Liang, Frederik Lassen, et al.
Life Science Alliance (2024) Vol. 7, Iss. 5, pp. e202302245-e202302245
Open Access | Times Cited: 2
Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy
Daowei Yang, Xinlei Sun, Rohan Moniruzzaman, et al.
Gastroenterology (2024) Vol. 167, Iss. 2, pp. 298-314
Closed Access | Times Cited: 2
The dual role of cellular senescence in human tumor progression and therapy
Liang Ma, Jie Yu, Yidian Fu, et al.
MedComm (2024) Vol. 5, Iss. 9
Open Access | Times Cited: 2
MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis
Chungui Xu, Weihao Lin, Qi Zhang, et al.
Molecular Medicine (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 2
SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition
Xinxin Song, Zhuan Zhou, Ammar D. Elmezayen, et al.
Science Advances (2024) Vol. 10, Iss. 50
Open Access | Times Cited: 2
A nonenzymatic dependency on inositol-requiring enzyme 1 controls cancer cell cycle progression and tumor growth
Iratxe Zuazo-Gaztelu, David A. Lawrence, Ioanna Oikonomidi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Targeting GFPT2 to reinvigorate immunotherapy in EGFR-mutated NSCLC
Luyao Ao, Wenjing Jia, Qixing Gong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
PTEN status determines therapeutic vulnerability to celastrol in cholangiocarcinoma
Yu‐Fei Pan, Lin Zhong, Min Wang, et al.
Phytomedicine (2024) Vol. 131, pp. 155790-155790
Closed Access | Times Cited: 1
Cetylpyridinium chloride triggers paraptosis to suppress pancreatic tumor growth via the ERN1-MAP3K5-p38 pathway
Hu Tang, Fangquan Chen, Wanli Gao, et al.
iScience (2024) Vol. 27, Iss. 8, pp. 110598-110598
Open Access | Times Cited: 1
Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS‐mutant Cancers
Yafang Wang, Lansong Xu, Lijun Ling, et al.
Advanced Science (2024)
Open Access | Times Cited: 1
SMURF1 mediates damaged lysosomal homeostasis by ubiquitinating PPP3CB to promote the activation of TFEB
Xia Qin, Xuan Liu, Zhong Lu, et al.
Autophagy (2024)
Closed Access | Times Cited: 1
PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Yiyang Li, Yike Wu, Shugeng Gao, et al.
Journal of Controlled Release (2024) Vol. 378, pp. 116-144
Closed Access | Times Cited: 1
The essential role of CCT2 in the regulation of aggrephagy
Jie Luo, Ze-Sen Feng, Ji‐Xin Tang
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 1
GFPT2 controls immune evasion in EGFR-mutated non-small cell lung cancer
Jiali Liu, Luyao Ao, Wenjing Jia, et al.
Research Square (Research Square) (2024)
Closed Access
Lysophosphatidylcholine acyltransferase 1 suppresses nanoclustering and function of KRAS
Neha Arora, Liang Hong, Wantong Yao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer
Xinchao Zhao, Yawen Zheng, Yufeng Wang, et al.
OncoTargets and Therapy (2024) Vol. Volume 17, pp. 1041-1057
Open Access
MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis
Junwei Zou, Xiuhua Shi, Zhaoying Wu, et al.
Translational Oncology (2024) Vol. 52, pp. 102235-102235
Closed Access
Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt
Noritaka Tanaka, Hiromichi Ebi
Cancer Science (2024)
Open Access
Decoding the proteostasis network in resistance to KRAS inhibitors
Xinxin Song, Zhuan Zhou, Kenneth D. Westover
The Innovation (2023) Vol. 4, Iss. 6, pp. 100526-100526
Open Access | Times Cited: 1
Rewired proteostasis in KRAS inhibitor resistance
Alex Eccleston
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 11, pp. 871-871
Closed Access
Sphingolipids and HSC fitness: enigma no more
Stephanie Z. Xie
Blood (2023) Vol. 142, Iss. 20, pp. 1674-1676
Open Access
Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors
A. Klein, Marc L. Mendillo
Cell chemical biology (2023) Vol. 30, Iss. 11, pp. 1334-1336
Open Access
Previous Page - Page 2

Scroll to top